Treatment for Macular Telangiectasia Type 2

Area of Science:

• Ophthalmology
• Retinal Diseases
• Medical Research

Background:

• Macular telangiectasia (MacTel) type 2 is a bilateral retinal disease of unknown origin.
• It is characterized by retinal degeneration and specific vascular changes, including ectatic capillaries and pigment plaques.
• Key features include macular pigment depletion and potential neovascularization.

Purpose of the Study:

• To describe the clinical characteristics and stages of Macular telangiectasia type 2.
• To evaluate potential treatment strategies for Macular telangiectasia type 2.
• To identify factors predicting visual outcome in patients with Macular telangiectasia type 2.

Main Methods:

• Funduscopic examination to identify characteristic retinal and vascular changes.
• Fluorescein angiography to detect capillary leakage.
• Optical coherence tomography to assess neurosensory atrophy.

Main Results:

• MacTel type 2 presents with reduced retinal transparency, crystalline deposits, foveal atrophy, and neovascular complexes.
• Leakage from telangiectatic macular capillaries is evident on angiography.
• Disease staging includes nonproliferative and proliferative (neovascular) forms.

Conclusions:

• Currently, no effective treatment exists for nonproliferative MacTel type 2.
• Intravitreal vascular endothelial growth factor inhibitors show potential benefit for patients with the proliferative stage and declining vision.
• Early intervention and small neovascular membrane size may predict better visual function outcomes.